Literature DB >> 7003384

Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.

F E Preston, S Whipps, C A Jackson, A J French, P J Wyld, C J Stoddard.   

Abstract

To compare the inhibitory effects of aspirin on prostaglandin synthesized by vessel walls and platelets, we obtained vein segments from five subjects before they were given 150 or 300 mg of aspirin and at various intervals afterward. We then measured prostacyclin (PGI2) synthesis with a radioimmunoassay for its stable metabolite, 6-keto-prostaglandin F1 alpha. Platelet production of thromboxane A2 was measured with a radioimmunoassay for its stable metabolite, thromboxane B2. Two hours after aspirin had been given, 81 to 100 per cent inhibition of PGI2 synthesis was demonstrated; 86 per cent inhibition was still evident in one subject tested eight hours after administration. Simultaneously, platelet production of thromboxane B2 was completely inhibited for more than 24 hours. We conclude that there is little difference between the initial inhibitory response of platelet cyclooxygenase and that of vessel-wall cyclooxygenase to these doses of aspirin. Our results also indicate that in male subjects the prolonged template bleeding time after aspirin is not the consequence of selective inhibition of platelet production of thromboxane.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7003384     DOI: 10.1056/NEJM198101083040203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  29 in total

Review 1.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 2.  Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.

Authors:  H Patscheke
Journal:  Blut       Date:  1990-05

3.  Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.

Authors:  Kelly E Johnson; Julia R Ceglowski; Harvey G Roweth; Jodi A Forward; Mason D Tippy; Saleh El-Husayni; Rajesh Kulenthirarajan; Michael W Malloy; Kellie R Machlus; Wendy Y Chen; Joseph E Italiano; Elisabeth M Battinelli
Journal:  Blood Adv       Date:  2019-01-22

Review 4.  The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.

Authors:  J A Oates
Journal:  Trans Am Clin Climatol Assoc       Date:  1990

5.  Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels.

Authors:  C Cerletti; M C Gambino; S Garattini; G de Gaetano
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

6.  Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function.

Authors:  F Bochner; D B Williams; P M Morris; D M Siebert; J V Lloyd
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

8.  Pharmacological interaction between nitroglycerin and aspirin after acute and chronic aspirin treatment of healthy subjects.

Authors:  E Rey; H D El-Assaf; M O Richard; S Weber; A Bourdon; G Picard; G Olive
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Inhibition of platelet function by a controlled release acetylsalicylic acid formulation--single and chronic dosing studies.

Authors:  M S Roberts; L J McLeod; P A Cossum; J H Vial
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Association of thromboxane A2 receptor gene polymorphisms with cerebral infarction in a Chinese population.

Authors:  Jing Zhao; Lan Zheng; Qingzhou Fei; Yi Fu; Yingfeng Weng; Hui Wu; Huanyin Li; Qi Jun; Jingshan Shao; Yuming Xu
Journal:  Neurol Sci       Date:  2013-03-02       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.